$AKER new breakout Pr. $3.22
Nasdaq CM ultra low float
Website
7:01 am Akers Biosciences signs distribution agreement for BreathScan OxiChek with Aero-Med, a division of Cardinal Health (CAH)Briefing.com(Mon 7:01AM EDT)
Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)Marketwired(Mon 7:00AM EDT)
Shares Outstanding: 5.42M
Float: 3.70M
% Held by Insiders: 19.40%
% Held by Institutions: 8.80%
Shares Short (as of May 31, 2016): 13.80K
Short Ratio (as of May 31, 2016): 0.60
Short % of Float (as of May 31, 2016): 0.30%
Shares Short (prior month): 11.63K
Headlines
Akers Biosciences, Inc., together with its subsidiaries, focuses on the development and sale of disposable diagnostic testing devices to facilitate time sensitive therapeutic decisions in the United States and internationally. The companys marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor weight loss; and PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin. Its marketed products also comprise seraSTAT, a blood cell separator; Tri-Cholesterol Check, a test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. The companys pipeline products consists of Breath Ketone Check, a disposable breath ketone device for diabetic monitoring, and management of senile dementia and alzheimers disease patients; Breath PulmoHealth Check, a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia to test sexually transmitted disease; and PIFA PLUSS TroponinI for the diagnosis of a myocardial infarction. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
Nasdaq CM ultra low float
Website
7:01 am Akers Biosciences signs distribution agreement for BreathScan OxiChek with Aero-Med, a division of Cardinal Health (CAH)Briefing.com(Mon 7:01AM EDT)
Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)Marketwired(Mon 7:00AM EDT)
Shares Outstanding: 5.42M
Float: 3.70M
% Held by Insiders: 19.40%
% Held by Institutions: 8.80%
Shares Short (as of May 31, 2016): 13.80K
Short Ratio (as of May 31, 2016): 0.60
Short % of Float (as of May 31, 2016): 0.30%
Shares Short (prior month): 11.63K
Headlines
Akers Biosciences, Inc., together with its subsidiaries, focuses on the development and sale of disposable diagnostic testing devices to facilitate time sensitive therapeutic decisions in the United States and internationally. The companys marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor weight loss; and PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin. Its marketed products also comprise seraSTAT, a blood cell separator; Tri-Cholesterol Check, a test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. The companys pipeline products consists of Breath Ketone Check, a disposable breath ketone device for diabetic monitoring, and management of senile dementia and alzheimers disease patients; Breath PulmoHealth Check, a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia to test sexually transmitted disease; and PIFA PLUSS TroponinI for the diagnosis of a myocardial infarction. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
